Every 10-Q that DiaMedica Therapeutics Inc. (DMAC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DMAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMAC filings page.
DiaMedica Therapeutics Inc. reported a larger loss for the quarter and first half of 2026 as it continued to advance its lead drug candidate DM199 in preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). For the six months ended June 30, 2026, the company recorded a net loss of $20.2 million, compared with $15.4 million a year earlier, driven mainly by higher research and development spending.
R&D expenses rose to $16.1 million for the first half of 2026 from $11.5 million, reflecting expansion of the ReMEDy2 AIS trial globally, additional reproductive toxicity testing to support the PE program, increased manufacturing activity, and higher share-based compensation. General and administrative expenses were relatively stable at $4.8 million versus $4.7 million. Operating cash outflow was $17.2 million in the first half.
As of June 30, 2026, DiaMedica held $43.5 million in cash, cash equivalents and marketable securities, working capital of $37.7 million, and shareholders’ equity of $38.3 million. Management expects these resources to fund planned operations for at least 12 months, while continuing the Phase 2 PE trial and the Phase 2/3 ReMEDy2 AIS trial, where enrollment for the interim analysis has reached 85% of the 200-participant threshold.
DiaMedica Therapeutics reported a net loss of $10.0 million for the quarter ended March 31, 2026, compared with $7.7 million a year earlier, driven mainly by higher research and development spending.
R&D expenses rose to $8.0 million from $5.7 million as the company expanded its Phase 2/3 ReMEDy2 trial in acute ischemic stroke and advanced DM199 into preeclampsia and fetal growth restriction. General and administrative costs were stable at $2.5 million.
The company had $51.3 million in combined cash, cash equivalents and marketable securities, working capital of $46.6 million and shareholders’ equity of $47.2 million. Management believes these resources will fund planned operations for at least the next 12 months while it continues DM199 clinical development, despite slower-than-expected enrollment in ReMEDy2 and an interim analysis currently estimated for the fourth quarter of 2026.
DiaMedica Therapeutics (DMAC) filed its Q3 2025 10-Q, highlighting a clinical-stage focus on DM199 for preeclampsia (PE) and acute ischemic stroke (AIS). For the nine months ended September 30, 2025, the company reported a net loss of $24.0 million and used $21.3 million in operating cash. As of September 30, 2025, cash, cash equivalents and marketable securities were $55.3 million, with working capital of $51.0 million.
R&D expenses were $6.4 million in Q3 (up from $5.0 million a year ago) and G&A was $2.6 million (up from $1.9 million), reflecting ongoing ReMEDy2 trial activities and PE program work. The company completed a July 2025 private placement of 8,606,425 shares at $3.50 for $30.1 million gross (~$30.0 million net) and sold 223,472 shares via its ATM for $1.6 million gross; up to $100 million may be sold under the ATM, with $98.4 million remaining as of quarter end.
In PE, interim Phase 2 results (N=28) showed DM199 appeared safe with blood pressure reductions. In AIS, ReMEDy2 site activations and enrollment remain slower than expected; interim analysis is estimated in the second half of 2026, and UK approval to conduct the study was received on August 28, 2025.
DiaMedica Therapeutics (DMAC) is a clinical-stage biopharmaceutical company developing DM199 for preeclampsia (PE) and acute ischemic stroke (AIS). Interim results from the investigator-sponsored Phase 2 PE Part 1a (N=28) showed DM199 appeared safe and well-tolerated, with no evidence of placental transfer and rapid, statistically significant reductions in blood pressure sustained up to 24 hours post-infusion. Preparations are underway to start Part 1b.
The ReMEDy2 Phase 2/3 adaptive AIS trial is ongoing but experiencing slower-than-expected site activations and enrollment due to staffing shortages, protocol criteria, prior hypotension events, and site retention of patients; the company is expanding its internal clinical team and global site footprint to mitigate delays. The adaptive design targets ~300 participants (interim analysis at 200) with a potential final sample up to 728.
Financially, DiaMedica reported a six-month net loss of $15.4 million, cash and marketable securities of $30.0 million and an accumulated deficit of $155.4 million as of June 30, 2025. In July 2025 the company completed a private placement raising net proceeds of $29.9 million, which management states, together with existing resources, should fund operations for at least the next 12 months. R&D and G&A expenses increased year-over-year as clinical activity expanded.